Immunovant (IMVT) Capital Expenditures (2019 - 2026)
Immunovant's Capital Expenditures was $8,000 in fiscal Q4 2026 (quarter ended Mar 31, 2026), down 96.0% from $201,000 a year earlier.
Powered by 
Analysis
Immunovant (IMVT) Capital Expenditures (2019 - 2026) Analysis & Trends
From fiscal Q2 2020 onward, Immunovant has reported Capital Expenditures for 24 quarters.
- Capital Expenditures shows a five-year compound annual growth rate of -48.0% (FY2021 to FY2026).
- In earlier fiscal years, Capital Expenditures was $759,000 in FY2025 (+110.8%), $360,000 in FY2024 (+82.7%), $197,000 in FY2023 (-22.4%) and $254,000 in FY2022 (+21.0%).
- Compared with a year earlier, Capital Expenditures was higher in four of the last five quarters, with growth averaging 151.3%.
- The best year-over-year quarter for Capital Expenditures over five years was fiscal Q4 2024 (growth of 476.9%); the worst was fiscal Q4 2026 (a decline of 96.0%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | -321.00 Mn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | -763.00 Mn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 112.20 Mn |
| 10 | Immunovant | 6.90 Bn | 6.90 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 180,000.00 |
| Sep 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Jun 30, 2023 | 45,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Dec 31, 2022 | 98,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | 118,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 44,000.00 |
| Jun 30, 2021 | 18,000.00 |
| Mar 31, 2021 | 95,000.00 |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | 39,000.00 |
API Access
Immunovant Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMVT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "IMVT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMVT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();